Loading
Life sciences · Journal article
Organic Process Research & Development · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract [18F]FFNP is a promising investigational radiopharmaceutical for PET imaging of progesterone receptor (PR) expression in breast cancer. [18F]FFNP PET imaging enables noninvasive assessment of PR expression and serves as a valuable diagnostic tool for determining the functional endocrine status of ER+ breast tumors to guide endocrine therapy. In this study, we report a robust and fully automated radiosynthesis of [18F]FFNP using a commercially available radiosynthesizer. The ratio of the mesylate precursor to the K2.2.2/K2CO3 complex was found to be critical for optimizing radiochemical yield. The optimized and automated radiosynthesis process was completed within 50 min and successfully passed three consecutive validation runs, producing [18F]FFNP activity in 19.52–23.91% decay-corrected radiochemical yields at the end of synthesis. Approximately 215–265 mCi (7.96–9.81 GBq) of [18F]FFNP activity was obtained with high radiochemical purity (99.65–99.72%) and molar activity (16.83–37.40 Ci/μmol [623–1384 GBq/μmol]) in our cGMP-compliant PET Radiochemistry facility. All drug product specifications passed quality control (QC) testing and met the requirements for clinical investigational use.